SEAN FENG: Open Payments
NPI 1417427535 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$374 in 14 payments from 13 companies in 2025. Trend: 2023 $628 · 2024 $597 · 2025 $374
Food & beverage: $374
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $67 |
| Alnylam Pharmaceuticals Inc. | 1 | $36 |
| Agios Pharmaceuticals, Inc. | 1 | $32 |
| SpringWorks Therapeutics, Inc. | 1 | $31 |
| GlaxoSmithKline, LLC. | 1 | $31 |
| Genentech USA, Inc. | 1 | $29 |
| Rigel Pharmaceuticals, Inc. | 1 | $27 |
| BeOne Medicines USA, Inc. | 1 | $23 |
| ABBVIE INC. | 1 | $23 |
| Genmab U.S., Inc. | 1 | $21 |
Products named: LYNPARZA, GIVLAARI, PYRUKYND, GOMEKLI, BLENREP, Polivy, TAVALISSE, BRUKINSA.
Industry payments across MA — which companies pay providers there.
